ArticleNanotheranostics2020
Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Article in Nanotheranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 39 citations in OpenAlex.
- Gold- or Silver-Nanoparticle SERS Platforms for Plasma-Based Diagnostics and AI-Driven Analysis.Sensors (Basel, Switzerland) · 2026Review
- Development of an ligase chain reaction-fluorescence-SERS multimodal biosensing workflow for ultrasensitive detection and single-base discrimination of KRAS ctDNA.Mikrochimica acta · 2026Article
- Plasmonic and surface-enhanced Raman nanobiosensors for quantitative molecular detection.Discover nano · 2026Review
- Next-Generation SERS Probes: Engineering Hotspots, Intelligent Molecular Targeting, and AI-Driven Spectral Analysis for Emerging Applications.Nanomaterials (Basel, Switzerland) · 2026Review
- Translational feasibility of a plasmonic microarray-based liquid biopsy for KRAS codon mutation detection across tissue, plasma, and urine in early colorectal cancer.NPJ precision oncology · 2026Article
- Surface-Enhanced Raman Spectroscopy for Biomedical Applications: Recent Advances and Future Challenges.ACS applied materials & interfaces · 2025Review
- SERS biosensors for liquid biopsy towards cancer diagnosis by detection of various circulating biomarkers: current progress and perspectives.Nano convergence · 2024Review
- Review
- ctDNA as a novel and promising approach for cancer diagnosis: a focus on hepatocellular carcinoma.EXCLI journal · 2023Review
- SERS characterization of colorectal cancer cell surface markers upon anti-EGFR treatment.Exploration (Beijing, China) · 2022Article
- Rapid Multiplex Strip Test for the Detection of Circulating Tumor DNA Mutations for Liquid Biopsy Applications.Biosensors · 2022Article
- cfDNA Sequencing: Technological Approaches and Bioinformatic Issues.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Current status of ctDNA in precision oncology for hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular diagnostic testing of KRAS and BRAF mutations has become critical in the management of colorectal cancer (CRC) patients. Some progress has been made in liquid biopsy detection of mutations in circulating tumor DNA (ctDNA), which is a fraction of circulating cell-free DNA (cfDNA), but slow analysis for DNA sequencing methods has limited rapid diagnostics. Other methods such as quantitative PCR and more recently, droplet digital PCR (ddPCR), have limitations in multiplexed capacity and the need for expensive specialized equipment. Hence, a robust, rapid and facile strategy is needed for detecting multiple ctDNA mutations to improve the management of CRC patients. To address this significant problem, herein, we propose a new application of multiplex PCR/SERS (surface-enhanced Raman scattering) assay for the detection of ctDNA in CRC, in a fast and non-invasive manner to diagnose and stratify patients for effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.